10 Overlooked Penny Stocks to Buy Right Now

Page 4 of 4

6. Prime Medicine, Inc. (NASDAQ:PRME)

Number of Hedge Fund Holders: 23

Upside Potential: 79.95%

Prime Medicine, Inc. (NASDAQ:PRME) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Multiple regulatory clearances across its gene-editing pipeline are prompting analysts to turn more constructive on the stock.

On June 29, 2026, H.C. Wainwright upgraded Prime Medicine, Inc. (NASDAQ:PRME) to “Buy” from “Neutral” with a price target of $8. The upgrade came after New Zealand’s Medicines and Medical Devices Safety Authority accepted the clinical trial application for PM577a, the company’s investigational therapy for Wilson’s disease. The firm called the clearance a meaningful de-risking event, noting it marks the first clinical authorization for an in vivo prime editing therapy from Prime Medicine.

That clearance, announced by the company on June 18, 2026, enables Prime Medicine, Inc. (NASDAQ:PRME) to begin a global Phase 1/2 study evaluating PM577a in adults and adolescents with Wilson Disease. CEO Allan Reine called the milestone a defining moment, pointing to PM577a’s potential to correct the disease at the genomic level with a one-time therapy. Chief Medical Officer Mohammed Asmal said the trial design draws on the company’s preclinical work, with proof-of-concept data expected in 2027.

Meanwhile, on June 22, 2026, the FDA granted Regenerative Medicine Advanced Therapy designation to PM359, Prime Medicine, Inc. (NASDAQ:PRME)’s stem cell therapy for p47phox-deficient chronic granulomatous disease (CGD), based on Phase 1/2 clinical data published in The New England Journal of Medicine. Reine said the designation supports engagement with the FDA toward a future Biologics License Application.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company that delivers genetic medicines to address the spectrum of diseases by deploying gene editing technology.

While we acknowledge the potential of PRME to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRME and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Overlooked Penny Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.

Page 4 of 4
1281292 - 11759070 - 1